0 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Motion Sickness by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 10 ongoing clinical trials involving Motion Sickness
Of the 10 trials,3 trials are in Phase II
Furthermore, 3 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Motion Sickness by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Motion Sickness, a Gastrointestinal condition. The largest number of ongoing clinical trials for Motion Sickness is conducted in North America. Middle East and Africa is the other prominent region engaged in Motion Sickness-related drug trials.

Repurposed Therapeutics Inc: The leading ongoing Motion Sickness related clinical trial sponsor

Repurposed Therapeutics Inc is the top sponsor for Motion Sickness-related ongoing clinical trials.

University of Texas MD Anderson Cancer Center, Medical Corps Israeli Defense Forces and Naval Medical Research Unit Dayton are among other notable clinical trial sponsors involved in Motion Sickness. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Motion Sickness

Meclizine hydrochloride, Acetaminophen and ondansetron hydrochloride (Lupisetron Plus) and Dimenhydrinate are among the key marketed drugs involving Motion Sickness.

Meclizine hydrochloride is a piperazine derivative, acts as an anti-emetic, anti-allergic agent and anti-histamine agent. It functions via Histamine H1 Receptor (HRH1) Antagonist mechanism of action. Meclizine hydrochloride is formulated as tablets for oral route of administration. Meclizine hydrochloride was first approved in 2010 and is marketed solely in the US by Jubilant Cadista Pharmaceuticals Inc.

Acetaminophen and ondansetron hydrochloride (Lupisetron Plus) is a fixed dose combination product acts asan analgesic, antipyretic and anti-emetic agent. It functions via 5-Hydroxytryptamine Receptor 3 (5HT3 or 5 HT3 Receptor or HTR3) Antagonist; Prostaglandin G/H Synthase 1 Inhibitor; Prostaglandin G/H Synthase 2 Inhibitor mechanism of action. Acetaminophen and ondansetron hydrochloride is formulated as tablets for oral route of administration. Acetaminophen and ondansetron hydrochloride is marketed solely in India by Lupin Ltd.